Montelukast Tarbis (Montelukast)

Montelukast blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotriene D4 from binding. This inhibition stops the cascade that leads to bronchoconstriction, mucus production, and vascular leakage, thereby reducing airway inflammation and allergic responses.

The specific dose of Montelukast Tarbis is determined by the prescribing clinician based on the patient’s age, weight, indication, and clinical response. Healthcare providers follow approved dosing guidelines, and patients should follow the prescriber’s instructions without alteration.

The pregnancy safety category for Montelukast is not definitively established. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential benefits and risks with their healthcare professional before using Montelukast Tarbis.

To order Montelukast Tarbis, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast is an oral leukotriene receptor antagonist, offering a convenient alternative to inhaled corticosteroids or long‑acting beta‑agonists for certain patients. While it is effective for mild‑to‑moderate asthma and allergic rhinitis, inhaled steroids remain the first‑line therapy for persistent asthma due to their broader anti‑inflammatory profile.

Montelukast Tarbis should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

Montelukast Tarbis is taken orally, usually once daily in the evening. The tablet should be swallowed whole with water and can be taken with or without food, following the prescriber’s directions.

Serious risks include neuropsychiatric events such as depression, suicidal thoughts, or mood changes, as well as severe allergic reactions like rash, angioedema, or anaphylaxis. Patients should seek immediate medical attention if they experience any of these symptoms.

Montelukast Tarbis is contraindicated in individuals with known hypersensitivity to montelukast or any of the tablet’s excipients. It should also be used with caution in patients with severe liver impairment or those taking strong CYP3A4 inducers, unless advised otherwise by a healthcare professional.